[go: up one dir, main page]

ES2038669T3 - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
ES2038669T3
ES2038669T3 ES198787307973T ES87307973T ES2038669T3 ES 2038669 T3 ES2038669 T3 ES 2038669T3 ES 198787307973 T ES198787307973 T ES 198787307973T ES 87307973 T ES87307973 T ES 87307973T ES 2038669 T3 ES2038669 T3 ES 2038669T3
Authority
ES
Spain
Prior art keywords
units
density
pharmaceutical formulation
baric
liberation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787307973T
Other languages
English (en)
Inventor
John Michael Newton
Jane Elizabeth Devereux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London School of Pharmacy Innovations Ltd
Original Assignee
London School of Pharmacy Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868622482A external-priority patent/GB8622482D0/en
Priority claimed from GB878708011A external-priority patent/GB8708011D0/en
Application filed by London School of Pharmacy Innovations Ltd filed Critical London School of Pharmacy Innovations Ltd
Application granted granted Critical
Publication of ES2038669T3 publication Critical patent/ES2038669T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL TIEMPO DE RESIDENCIA EN EL ESTOMAGO HUMANO DE UNIDADES SOLIDAS FARMACEUTICAS DE LIBERACION GASTRICA CONTROLADA, AUMENTA SIGNIFICATIVAMENTE SI LAS UNIDADES TIENEN UNA DENSIDAD QUE ES MUCHO MAS ALTA QUE LA NORMAL. UNA FORMA DE ADMINISTRACION ORAL PREFERIDA CONFORME A LA INVENCION COMPRENDE UNA CAPSULA U OTRA FORMA DE DOSIFICACION QUE TIENENUNA DIMENSION SUPERIOR A 2 MM Y CONTIENE UNO O MAS DE DICHAS UNIDADES. LA DENSIDAD DE CADA UNIDAD ES PREFERIBLEMENTE POR LO MENOS 2,5 Y USUALMENTE POR LO MENOS 2,7 G/ML Y PUEDEN CONSEGUIRSE DE FORMA CONVENIENTE INCLUYENDO AL MENOS EL 50% EN PESO DE UN AGENTE DE CARGA TAL COMO EL SULFATO BARICO.
ES198787307973T 1986-09-18 1987-09-09 Formulacion farmaceutica. Expired - Lifetime ES2038669T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868622482A GB8622482D0 (en) 1986-09-18 1986-09-18 Pharmaceutical formulation
GB878708011A GB8708011D0 (en) 1987-04-03 1987-04-03 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES2038669T3 true ES2038669T3 (es) 1993-08-01

Family

ID=26291305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787307973T Expired - Lifetime ES2038669T3 (es) 1986-09-18 1987-09-09 Formulacion farmaceutica.

Country Status (19)

Country Link
US (1) US4938967A (es)
EP (1) EP0265061B1 (es)
KR (1) KR890004686B1 (es)
AT (1) ATE71293T1 (es)
AU (1) AU606353B2 (es)
BE (1) BE1000616A5 (es)
CA (1) CA1302259C (es)
CH (1) CH674146A5 (es)
DE (1) DE3775880D1 (es)
DK (1) DK488287A (es)
ES (1) ES2038669T3 (es)
FR (1) FR2604090B1 (es)
GB (1) GB2196252B (es)
GR (1) GR3004268T3 (es)
HU (1) HU202101B (es)
IL (1) IL83897A (es)
IT (1) IT1211484B (es)
NZ (1) NZ221805A (es)
PT (1) PT85747B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
DK165090D0 (da) * 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
GB9018839D0 (en) * 1990-08-29 1990-10-10 Newton John M Slow release compositions
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
AU4993893A (en) * 1992-07-31 1994-03-03 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
CA2141788C (en) * 1992-08-04 2001-12-11 James M. Dunn Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
FR2703908B1 (fr) * 1993-04-13 1995-06-02 Asta Medica Ag Forme pharmaceutique pour administration rectale de composés pharmacologiquement actifs.
US6706188B2 (en) 1993-05-03 2004-03-16 Amersham Biociences Ab Process and means for down stream processing
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
AR014765A1 (es) * 1998-03-23 2001-03-28 Gen Mills Marketing Inc Composicion de matriz comestible con textura masticable, producto comestible y masticable, composicion comestible, cobertura de alimentos y metodo para la fabricacion de productos comestibles
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
US20050079214A1 (en) * 1999-09-01 2005-04-14 John Cooker Oral delivery system and method for making same
US20040101540A1 (en) * 1999-09-01 2004-05-27 John Cooker Oral delivery system and method for making same
CA2383212C (en) 1999-09-02 2008-11-25 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2001257359A1 (en) 2000-04-27 2001-11-07 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US6569808B2 (en) * 2001-07-30 2003-05-27 Lee F. Klinger Methods and compositions useful for bryophyte remediation to improve forest health and growth
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US20070102672A1 (en) * 2004-12-06 2007-05-10 Hamilton Judd D Ceramic radiation shielding material and method of preparation
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US7803413B2 (en) * 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
WO2007089511A2 (en) 2006-01-27 2007-08-09 Yale University Fast acting inhibitor of gastric acid secretion
CN101984745B (zh) * 2007-09-07 2013-08-14 Qlt股份有限公司 用于持续释放治疗药物的药物核心
WO2010011712A1 (en) * 2008-07-22 2010-01-28 General Mills, Inc. Fruit products containing omega-3 fatty acids
PL2403482T3 (pl) * 2009-03-04 2018-06-29 Emplicure Ab Preparat odporny na nadużywanie
DK2427177T3 (en) 2009-05-08 2018-06-18 Emplicure Ab Composition for prolonged drug delivery comprising geopolymer binder
CA2762824C (en) * 2009-06-05 2017-10-10 General Mills, Inc. Encapsulated omega-3 fatty acids for baked goods production
KR20140003405A (ko) 2010-09-07 2014-01-09 오렉쏘 에이비 경피 약물 투여 장치
US20170172946A1 (en) * 2015-12-21 2017-06-22 Stephan Hau Micro-solid phase extraction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA614091A (en) * 1956-11-05 1961-02-07 Commonwealth Scientific And Industrial Research Organization Time delay pill for ruminant
GB936386A (en) * 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
CH582002A5 (es) * 1972-06-09 1976-11-30 Purdue Research Foundation
GB1590574A (en) * 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
GB1590573A (en) * 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
GB2015875B (en) * 1978-02-24 1982-10-20 Novex Foreign Trade Co Ltd Solid oral pharaceutical product with increased efficacy and predetermined steady state of solubility
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
MX6021E (es) * 1979-09-12 1984-09-24 Lilly Co Eli Dispositivo para administrar compuestos farmaceuticos de liberacion controlada a los rumiantes cuando es retenido en la porcion reticular del estomago de los mismos
GB2100602B (en) * 1981-06-24 1984-11-14 May & Baker Ltd Device for delivering biologically active substances to the digestive tract.
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
GB2123690A (en) * 1982-07-20 1984-02-08 Nat Res Dev Sustained release device
GB2123693B (en) * 1982-07-20 1987-05-13 Nat Res Dev Sustained release device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
FR2560768A1 (fr) * 1984-03-07 1985-09-13 Crb Virbac Sa Dispositif a liberation programmee
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom

Also Published As

Publication number Publication date
GB8721186D0 (en) 1987-10-14
CH674146A5 (es) 1990-05-15
FR2604090A1 (fr) 1988-03-25
GR3004268T3 (es) 1993-03-31
DK488287A (da) 1988-03-19
IL83897A (en) 1991-06-10
FR2604090B1 (fr) 1990-06-15
EP0265061A1 (en) 1988-04-27
HU202101B (en) 1991-02-28
AU7848187A (en) 1988-03-24
EP0265061B1 (en) 1992-01-08
NZ221805A (en) 1991-02-26
KR890004686B1 (ko) 1989-11-25
GB2196252B (en) 1990-10-17
IT1211484B (it) 1989-11-03
PT85747B (pt) 1991-02-08
GB2196252A (en) 1988-04-27
HUT45194A (en) 1988-06-28
ATE71293T1 (de) 1992-01-15
DE3775880D1 (es) 1992-02-20
PT85747A (en) 1987-10-01
KR880003617A (ko) 1988-05-28
US4938967A (en) 1990-07-03
BE1000616A5 (fr) 1989-02-21
IT8767796A0 (it) 1987-09-17
DK488287D0 (da) 1987-09-17
AU606353B2 (en) 1991-02-07
IL83897A0 (en) 1988-02-29
CA1302259C (en) 1992-06-02

Similar Documents

Publication Publication Date Title
ES2038669T3 (es) Formulacion farmaceutica.
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
DK0490944T3 (da) Transmucosal doseringsform
DK20488D0 (da) Farmaceutiske praeparater med forlaenget afgivelse
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
KR890004705A (ko) 항바이러스성 제제
GR1000989B (el) Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.
ES2042831T3 (es) Procedimiento de preparacion de una composicion farmaceutica para el tratamiento de la osteoporosis.
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
KR910004190A (ko) 온단세트론의 신규 의학 용도
Shambaugh Jr The diagnosis and treatment of active cochlear otosclerosis1
KR830008678A (ko) 진통 조성물
KR880002521A (ko) 약제 제형
KR910004181A (ko) 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태
Glick et al. Dental caries, periodontal abscesses, and extensive cranial osteitis in a captive lowland gorilla (Gorilla gorilla gorilla)
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
BRPI0515833A (pt) oligonucleotìdeos osteogênicos e seus usos
Kuznetsova et al. Benzofurocaine analgesia in acute myocardial infarct
RU97110383A (ru) Способ профилактики и лечения атеросклероза
KR890014121A (ko) 사람의 골공증(骨孔症) 치료를 위한 방법과 조성물
UA51022A (uk) М'яка желатинова капсула
AR043470A2 (es) Una composicion farmaceutica para ser usada como anticonceptivo
TH43012B (th) รูปแบบขนาดใช้ยาที่เป็นเม็ดแบบหลายหน่วย i

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 265061

Country of ref document: ES